ALK and non-small cell lung carcinoma: NSCLC still has a poor prognosis, and immunotherapy (IMT) has become part of the treatment of patients with no driver alterations (epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)) (41).